CLBT vs. LLY
CLBT (Cellebrite DI Ltd.) and LLY (Eli Lilly and Company) are both stocks. CLBT operates in Software - Infrastructure (Technology), while LLY operates in Drug Manufacturers - General (Healthcare). Over the past 3 years, CLBT returned 23.87%/yr vs 37.33%/yr for LLY. Their 0.09 correlation means their historical movements had little consistent relationship.
Performance
CLBT vs. LLY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLBT achieves a -18.19% return, which is significantly lower than LLY's 7.26% return.
CLBT
- 1D
- 1.24%
- 1M
- -4.53%
- 6M
- 0.27%
- YTD
- -18.19%
- 1Y
- 5.51%
- 3Y*
- 23.87%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 7.22%
LLY
- 1D
- -0.53%
- 1M
- -3.60%
- 6M
- 11.14%
- YTD
- 7.26%
- 1Y
- 56.33%
- 3Y*
- 37.33%
- 5Y*
- 37.67%
- 10Y*
- 32.12%
- ALL TIME*
- 16.04%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $16.88M | $22.74M | $28.71M | |
| $2.62B | $2.84B | $3.35B |
CLBT vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CLBT Cellebrite DI Ltd. | -18.19% | -18.16% | 154.39% | 98.62% | -45.64% | -23.40% |
LLY Eli Lilly and Company | 7.26% | 40.25% | 33.30% | 60.91% | 34.26% | 5.64% |
Correlation
The correlation between CLBT and LLY is -0.07, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | -0.07 |
Correlation (3Y) Balances recent behavior with more history. | 0.11 |
Correlation (All Time) Calculated using the full available price history since Aug 31, 2021 | 0.09 |
The correlation between CLBT and LLY shifts across timeframes, from -0.07 (1 year) to 0.11 (3 years), reflecting how their relationship changes across market environments.
Fundamentals
CLBT:
$3.68B
LLY:
$1.08T
CLBT:
$0.29
LLY:
$28.16
CLBT:
51.54
LLY:
40.80
CLBT:
0.10
LLY:
0.82
CLBT:
7.46
LLY:
14.27
CLBT:
7.28
LLY:
32.99
CLBT:
$496.43M
LLY:
$72.25B
CLBT:
$416.33M
LLY:
$59.75B
CLBT:
$84.98M
LLY:
$32.97B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLBT vs. LLY — Risk / Return Rank
CLBT
LLY
CLBT vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Cellebrite DI Ltd. (CLBT) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLBT | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.38 | ||
| Sortino ratioReturn per unit of downside risk | -1.53 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.28 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | 0.13 | 2.44 | -2.32 |
| Martin ratioReturn relative to average drawdown | 0.25 | 6.60 | -6.35 |
Loading charts...
Drawdowns
CLBT vs. LLY - Drawdown Comparison
The maximum CLBT drawdown since its inception was -67.74%, roughly equal to the maximum LLY drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for CLBT and LLY.
Loading charts...
Drawdown Indicators
| CLBT | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.74% | -68.24% | +0.50% |
Max Drawdown (1Y)Largest decline over 1 year | -43.61% | -23.18% | -20.43% |
Max Drawdown (3Y)Largest decline over 3 years | -57.58% | -34.48% | -23.10% |
Max Drawdown (5Y)Largest decline over 5 years | — | -34.48% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -34.48% | — |
Current DrawdownCurrent decline from peak | -43.27% | -7.02% | -36.25% |
Average DrawdownAverage peak-to-trough decline | -34.78% | -19.17% | -15.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.74% | 8.56% | +13.18% |
Volatility
CLBT vs. LLY - Volatility Comparison
Cellebrite DI Ltd. (CLBT) has a higher volatility of 11.04% compared to Eli Lilly and Company (LLY) at 8.88%. This indicates that CLBT's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLBT | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.04% | 8.88% | +2.16% |
Volatility (6M)Calculated over the trailing 6-month period | 41.53% | 27.69% | +13.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 53.38% | 38.37% | +15.01% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.19% | 32.64% | +17.55% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 50.19% | 30.37% | +19.82% |
Dividends
CLBT vs. LLY - Dividend Comparison
CLBT has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.56%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CLBT Cellebrite DI Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
LLY Eli Lilly and Company | 0.56% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Financials
CLBT vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Cellebrite DI Ltd. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLBT vs. LLY - Profitability Comparison
CLBT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Cellebrite DI Ltd. reported a gross profit of 105.88M and revenue of 128.30M. Therefore, the gross margin over that period was 82.5%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
CLBT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Cellebrite DI Ltd. reported an operating income of 9.23M and revenue of 128.30M, resulting in an operating margin of 7.2%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
CLBT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Cellebrite DI Ltd. reported a net income of 10.94M and revenue of 128.30M, resulting in a net margin of 8.5%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
Frequently Asked Questions
CLBT and LLY have a correlation of -0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLBT has higher volatility (11.04%) compared to LLY (8.88%). In terms of maximum drawdown, CLBT dropped -67.74% vs LLY's -68.24%.
LLY currently has the higher Sharpe Ratio (1.48 vs 0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLBT and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer